# Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents

Study · id `cardio:ct-nct01711931` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01711931](<https://clinicaltrials.gov/study/NCT01711931>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01711931

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

## Technical summary

Registry record NCT01711931. Randomized; single masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2013-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 240 participants (enrolled count; ClinicalTrials.gov record NCT01711931, source copy `cardio:ctgov-nct01711931-2021-10-22`, retrieved 2026-10-26)
- Start date: 2012-10 (registry gives no type) (ClinicalTrials.gov record NCT01711931, source copy `cardio:ctgov-nct01711931-2021-10-22`, retrieved 2026-10-26)
- Primary completion: 2013-12 (actual) (ClinicalTrials.gov record NCT01711931, source copy `cardio:ctgov-nct01711931-2021-10-22`, retrieved 2026-10-26)
- Completion: 2013-12 (actual) (ClinicalTrials.gov record NCT01711931, source copy `cardio:ctgov-nct01711931-2021-10-22`, retrieved 2026-10-26)
- Countries: Switzerland (ClinicalTrials.gov record NCT01711931, source copy `cardio:ctgov-nct01711931-2021-10-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01711931-2021-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents
- Acronym: EVERBIOII
- Condition: Coronary Artery Disease
- Intervention (Device): Implantation of everolimus-eluting bioresorbable vascular scaffold stent
- Intervention (Device): Implantation of everolimus-eluting stents
- Intervention (Device): Implantation of biolimus-eluting stents
- Lead sponsor: University of Freiburg
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds (`cardio:pubmed-25720622`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial (`cardio:pubmed-26766027`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 62ae0c95ef590b2399fe9b19a2294b2b66cc322909959529abaa5b243fe5c18c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
